Novo Nordisk’s meteoric rise has been met with a wave of ringing endorsements from customers who have seen years of struggles with obesity solved in a flash with the help of Ozempic and Wegovy. At least, that’s the opinion of those who can afford or even access the pricey drugs.
Novo Nordisk CEO Lars Fruergaard Jørgensen called out Americans’ struggles to navigate the “complex U.S. healthcare system” and that “no company alone could solve such vast and complicated policy challenges,” defending the price of his weight loss-aiding drugs that vastly outstrip prices in Europe and the U.K.
